Population-based and opportunistic screening and eradication of Helicobacter pylori -: An analysis using trial baseline data

被引:9
作者
Mason, JM [1 ]
Moayyedi, P
Young, PJ
Duffett, S
Crocombe, W
Drummond, MF
Axon, ATR
机构
[1] Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO1 5DD, N Yorkshire, England
[2] Univ Leeds, Ctr Digest Dis, Leeds, W Yorkshire, England
[3] Gen Infirm Leeds, Leeds, W Yorkshire, England
[4] Univ York, Dept Hlth Sci, York YO1 5DD, N Yorkshire, England
[5] Univ Leeds, Yorkshire Clin Trials & Res Unit, Leeds, W Yorkshire, England
关键词
Helicobacter pylori; economics; mass screening;
D O I
10.1017/S0266462399015445
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To examine whether screening and eradication of Helicobacter pylori by population-based invitation or opportunistic screening by general practitioners reduces costs to the National Health Service (NHS) of treating dyspepsia. Methods: A limited dependent, variable, two-step regression analysis was used to explore the baseline annual health care costs of dyspepsia for men and women aged 40-49 enrolled in the Leeds H. pylori screening and eradication trial. Results: Epidemiological and clinical questionnaires, general practitioner notes, and C-13 urea breath test results were available for 4,754 individuals. After adjusting for covariates, H. pylori was associated with a 6.7% increased probability of incurring gastrointestinal-related NHS costs to (p<.0001) in the population aged 40-49. Additionally, H pylori increased average costs: in those who seek medical care to (p = .001). In consequence, H. pylori is associated with an average increased cast to the NHS of pound 0.30 per year (95% Cl: pound 0.17 to pound 0.45) per adult aged 40-49. In those consulting for dyspepsia, the increased cost to the NHS was pound 1.04 per year (95% Cl: pound 0.42 to pound 1.75) per patient. The cost of population screening and treatment would not be recovered in reduced dyspepsia costs in the lifetime of those screened. Assuming laboratory-based serology screening is used opportunistically in patients presenting with dyspepsia, it is estimated that costs would be recouped in 18 years. Conclusions: This observational data set suggests that the costs of screening and treatment in all individuals aged 40-49 or in those presenting in primary care with dyspeptic symptoms are unlikely to be attractive on the basis of cost savings alone.
引用
收藏
页码:649 / 660
页数:12
相关论文
共 11 条
[1]   Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age [J].
Briggs, AH ;
Sculpher, MJ ;
Logan, RPH ;
Aldous, J ;
Ramsay, ME ;
Baron, JH .
BRITISH MEDICAL JOURNAL, 1996, 312 (7042) :1321-1325
[2]  
*BRIT MED ASS ROYA, 1997, BRIT MED ASS ROYAL P
[3]  
*BUR STABL IS, 1998, BUR STABL IS AN
[4]  
*CIPFA HFM, 1997, HLTH SERV FIN DAT 19
[5]  
JONES AM, 1998, HLTH ECONOMETRICS
[6]  
MOAYYEDI P, 1995, EUR J GASTROEN HEPAT, V7, P835
[7]  
Moayyedi P, 1998, BRIT MED BULL, V54, P243
[8]   Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection [J].
Moayyedi, P ;
Carter, AM ;
Catto, A ;
Heppell, RM ;
Grant, PJ ;
Axon, ATR .
BRITISH MEDICAL JOURNAL, 1997, 314 (7074) :119-119
[9]  
MOORE RA, 1995, HELICOBACTER PYLORI
[10]  
NETTEN A, 1997, UNIT COSTS HLTH SOCI